QQ客服 官方微博 反馈留言

	The 104‐week efficacy and safety of telbivudine‐based optimization strategy in chronic hepatitis B patients: A randomized, controlled study
	Sun, Jian; Xie, Qing; Tan, Deming; Ning, Qin; Niu, Junqi; Bai, Xuefan; Fan, Rong; Chen, Shijun; Cheng, Jun; Yu, Yanyan
刊名	Hepatology
	2014
卷号	59期号:4页码:1283-1292
ISSN号	1527-3350
DOI	10.1002/hep.26885
URL标识	查看原文
WOS记录号	WOS:000333249800013
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3317085
专题	中南大学
作者单位	1.[Fan, Rong 2.Hou, Jinlin 3.Sun, Jian] Southern Med Univ, Nanfang Hosp, Hepatol Unit, Guangzhou 510515, Guangdong, Peoples R China.
推荐引用方式 GB/T 7714	Sun, Jian,Xie, Qing,Tan, Deming,et al. The 104‐week efficacy and safety of telbivudine‐based optimization strategy in chronic hepatitis B patients: A randomized, controlled study[J]. Hepatology,2014,59(4):1283-1292.
APA	Sun, Jian.,Xie, Qing.,Tan, Deming.,Ning, Qin.,Niu, Junqi.,...&Hou, Jinlin*.(2014).The 104‐week efficacy and safety of telbivudine‐based optimization strategy in chronic hepatitis B patients: A randomized, controlled study.Hepatology,59(4),1283-1292.
MLA	Sun, Jian,et al."The 104‐week efficacy and safety of telbivudine‐based optimization strategy in chronic hepatitis B patients: A randomized, controlled study".Hepatology 59.4(2014):1283-1292.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。